San Diego-based Viking Therapeutics marked alone as a serious competitor within the weight loss drug current market in February soon after revealing promising information from the mid-phase trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when supplied like a weekly injection and in March the com